ULCERATIVE COLITIS

This early study tests CP101, an oral drug made from healthy donor stool, in 30 adults with mild-to-moderate ulcerative colitis. The goal is to see if it safely restores healthy gut bacteria and improves symptoms. Participants get either a short or extended course of CP101 and ar…

This study tests guselkumab, a drug that targets inflammation, in over 1,000 people with moderate to severe ulcerative colitis. Participants receive either guselkumab or a placebo to see if the drug can improve symptoms and lead to remission. The goal is to find a new treatment o…

This study follows about 500 adults with moderate to severe ulcerative colitis who are starting filgotinib, a medication that controls disease by reducing inflammation. Researchers are tracking how long patients stay on the drug, how well it works, and its impact on quality of li…

This study tests whether transplanting healthy donor stool into the gut can help people with ulcerative colitis, a chronic bowel disease. About 150 adults with active or steroid-dependent disease will receive either real fecal transplants or a sham procedure. The goal is to see i…

This early-stage study tests whether delivering a patient's own stem cells directly into the artery that supplies the colon is safe for people with moderate to severe ulcerative colitis. Twenty adults who have not responded to at least two standard treatments will receive one dos…

This study looks at the long-term safety and effectiveness of a daily pill called ABX464 for people with moderate to severe ulcerative colitis. About 200 participants who already improved in earlier studies will take the drug for up to 54 months. The goal is to see if ABX464 can …

This Phase 2 trial tests Aquamin®, a mineral supplement from red marine algae, in 40 people with mild ulcerative colitis or those in remission. Researchers want to see if it improves symptoms, quality of life, and markers of inflammation. Participants take 4 capsules daily for a …

This study tests an oral drug called TAK-279 (Zasocitinib) in 207 adults with moderate-to-severe ulcerative colitis. For the first 12 weeks, some get the drug and some get a placebo. After that, everyone gets the drug for up to a year. The goal is to see if it reduces bowel infla…

This study looks at whether the probiotic VSL#3 can change how bile acids work in people with Crohn's disease or ulcerative colitis. About 79 participants will take two sachets of VSL#3 daily for six weeks. Researchers will measure bile acid levels in blood and stool to see if th…

This study tests whether transplanting healthy donor stool into the colon can help people with ulcerative colitis achieve long-term symptom control without steroids. Thirty participants aged 10 to 80 will receive the transplant via colonoscopy or capsules. The goal is to see if t…

This study compares two approved drugs, risankizumab and vedolizumab, in about 530 adults with moderate to severe ulcerative colitis who have not tried targeted therapies before. Participants will receive one of the two drugs for about a year. The main goal is to see which drug b…

This study looks at how well and how safely the drug mirikizumab works over the long term (up to 3 years) for people with moderate to severe ulcerative colitis. About 1,058 adults who were already in earlier studies will continue treatment. The goal is to see if the drug can keep…

This study tests whether using a computer dashboard to guide infliximab dosing is more effective and safer than standard dosing for people with Crohn's disease or ulcerative colitis. About 124 participants will receive either dashboard-guided or standard treatment, with the goal …

This study tests whether a plant-based resistant starch, tailored to each child's needs, can help restore a healthier balance of gut bacteria in children with Crohn's disease or ulcerative colitis. About 80 children will receive either the starch or a placebo for several months. …

This study tests a digital health system that reminds people with inflammatory bowel disease (IBD) to take their medication and lets them report symptoms. About 123 adults starting a new oral or injectable treatment will use the system or get standard care for 12 months. The goal…

This study tests whether giving vedolizumab every 4 weeks instead of every 8 weeks can help Japanese patients with moderate to severe ulcerative colitis or Crohn's disease whose symptoms returned during standard treatment. About 56 participants will receive the drug intravenously…

This study was designed to see if adding MitoQ (an antioxidant supplement) to standard treatment can help children and teens with mild-to-moderate ulcerative colitis. Participants would have taken MitoQ or a placebo daily for 24 weeks, alongside their usual medication. The goal w…

This study looks at whether a gluten-free diet can help people with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). Researchers will track changes in symptoms, gut bacteria, and lab results in 60 adults over time. The goal is to see if avoiding gluten c…

This study tests an oral medication called tofacitinib in children aged 2 to 17 with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and bleeding. The goal is to see if the drug can bring the disease into remission (no symptoms and healed gut l…

This study tests an experimental drug called ALTB-268 in 50 adults with moderate-to-severe ulcerative colitis that did not improve with biologic therapies. The goal is to see if the drug can reduce disease activity, measured by a symptom and scope score. Participants receive the …

This study tests a new drug called MK-7240 (tulisokibart) in about 1020 people with moderate to severe ulcerative colitis, a chronic bowel disease. Participants receive either the drug or a placebo to see if it helps achieve remission (fewer symptoms and healed gut lining) at 12 …

This study looks at whether taking a common ulcerative colitis medication (5-ASA) in the morning versus the evening can better control hidden inflammation and improve gut health. About 32 adults with inactive ulcerative colitis but signs of low-level inflammation will take their …

This study looks at the long-term safety of filgotinib, a drug for ulcerative colitis, in over 1,100 adults who already took part in a filgotinib trial. The main goal is to track side effects and lab test changes over time. Participants must have completed a prior filgotinib stud…

This study tests a new drug called lutikizumab for people with moderate to severe ulcerative colitis, a condition causing inflammation and bleeding in the colon. About 156 adults will receive either lutikizumab or the standard drug adalimumab to see which works better and is safe…

This study tests whether a plant-based starch, tailored to each child's needs, can help restore a healthier gut microbiome in children with inflammatory bowel disease (Crohn's or colitis). About 100 children with mild disease or in remission will receive the starch for 6 months. …

This study looks at whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard treatment can help people with severe ulcerative colitis or hard-to-treat inflammatory bowel disease. About 44 adults will be randomly assigned to get either …

This study looks at the long-term safety and effectiveness of the drug etrasimod for people with moderate to severe ulcerative colitis. Participants had already taken part in earlier studies and will continue taking etrasimod for up to 2 years. The goal is to see if the drug can …

This study tests a new drug called rosnilimab in 132 adults with moderate to severe ulcerative colitis. The goal is to see if it can reduce disease activity and improve symptoms compared to a placebo. Participants must have tried other treatments without success. The trial is act…

This study tests an experimental drug called emvistegrast (GS-1427) in about 228 adults with moderate to severe ulcerative colitis. Participants receive either the drug or a placebo, and researchers check if symptoms improve after 12 weeks. The goal is to see if the drug can redu…

This study tests whether a daily pill called ABX464 can help people with moderate-to-severe ulcerative colitis stay in remission. Over 1,100 adults who completed an earlier treatment phase will take either 25 mg, 50 mg, or a placebo for 44 weeks. The goal is to see if the drug sa…

This study tests an oral medication called upadacitinib in children aged 2 to 17 with moderate-to-severe ulcerative colitis who have not improved with standard treatments. The goal is to see if the drug can reduce inflammation and control symptoms like diarrhea and bleeding. Part…

This study tests whether a fecal transplant (FMT) can safely and effectively treat recurrent C. difficile infections in children, including those with inflammatory bowel disease (IBD). Researchers will give FMT to 250 children aged 3-21 and track whether the infection comes back.…

This study tests whether adding high-dose vitamin D3 to standard anti-TNF therapy can improve symptoms and reduce inflammation in people with active Crohn's disease or ulcerative colitis. About 100 adults starting anti-TNF treatment will receive either vitamin D3 or a placebo for…

This study tests whether atorvastatin, a widely used cholesterol medication, can reduce the risk of colon cancer in people with long-standing ulcerative colitis who carry a specific genetic mutation (P53). About 42 participants will take either atorvastatin or a placebo for a per…

This study looks at whether a personalized 24-week exercise program can reduce fatigue, improve quality of life, and ease bowel symptoms in children with inflammatory bowel disease (IBD). About 70 children will take part, split into two groups based on their current exercise habi…

This registry is following over 2,200 adults with inflammatory bowel disease (IBD) across North America to see how approved treatments work in everyday practice. Researchers are collecting data on disease patterns, complications, and patient outcomes. The goal is to better unders…

This study looks at whether continuous heart rate variability (HRV) monitoring can predict how well patients with inflammatory bowel disease (IBD) respond to biologic therapies like infliximab or vedolizumab. Researchers will track HRV in 100 patients starting treatment and compa…

This study looks at whether regular text message check-ins and the ability to text your IBD care team can improve disease management and quality of life. About 900 people with Crohn's disease or ulcerative colitis will take part. Some will get extra symptom surveys and texting ac…

This study looks at how the drug infliximab behaves in the body of people hospitalized with severe ulcerative colitis. Researchers measure drug levels in blood, stool, and colon tissue, along with changes in proteins and genes. The goal is to better understand how the drug works,…

This study observes 562 adults with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who are starting or switching to Hyrimoz®, a biosimilar of adalimumab. Researchers will track how many patients continue the treatment after 6 months and why some stop, such as …

This study is observing over 1,000 adults with ulcerative colitis or Crohn's disease in Brazil who are taking or have taken vedolizumab. The goal is to see how long people stay on the treatment and what other therapies they have used. No new treatments are given; it is purely a r…

This 5-year observational study is following 15,000 adults and children with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, in real-world clinics. Researchers are collecting data on disease patterns, treatment use, and patient outcomes to bett…

This study tests a program to help teenagers with Crohn's disease or ulcerative colitis move from pediatric to adult healthcare. About 90 teens aged 16 to 17.5 will either get the program (which includes a navigator, skills training, and education) or standard care. The goal is t…

This study follows 535 adults with moderate-to-severe ulcerative colitis who are taking or will take Simponi. The goal is to monitor long-term safety risks, such as serious side effects, infections, and cancers. Participants continue their usual treatment, and no new therapy is t…

This study reviews the medical records of 4,000 adults with ulcerative colitis to understand which treatments doctors prescribe and how well they control inflammation. Researchers will also create an updated treatment roadmap based on real-world results. The goal is to improve lo…

This study is watching 500,000 adults with chronic gut conditions like Crohn's disease, ulcerative colitis, and eosinophilic GI disease. Researchers are collecting health records and patient reports to learn how these diseases progress and how well treatments work. No new treatme…

This study is testing a special thermal probe that measures temperature changes in the lining of the colon during a routine colonoscopy. The goal is to see if the probe can detect inflammation in people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerati…

This study looks at whether taking extra random biopsies during a colonoscopy helps find precancerous growths in people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. About 1,600 participants will be randomly assigned to one of two biopsy…

This study follows nearly 5,000 children with Crohn's disease, ulcerative colitis, or indeterminate colitis to monitor the long-term safety of their treatments, including the drug infliximab. Researchers collect information on side effects, disease activity, and quality of life o…